Curaleaf Holdings Inc., - CEO, Joe Lusardi
CEO, Joe Lusardi
Source: The Business Journals
  • Cannabis company Curaleaf (CSE:CURA) has completed its acquisition of three Arrow Alternative Care dispensaries
  • The Arrow dispensaries are located in the Connecticut cities of Hartford, Milford, and Stamford
  • Like Curaleaf’s dispensaries, the Arrow dispensaries will operate as essential businesses during the COVID-19 pandemic
  • Arrow has also implemented safety measures to protect employees and customers during this time
  • Curaleaf’s share price is up 5.25 per cent, and is currently trading for $5.41 per share

Cannabis company Curaleaf (CSE:CURA) has announced its completed acquisition of three Arrow Alternative Care dispensaries in Connecticut. 

The three dispensaries are located in key metro areas, in the cities of Hartford, Milford, and Stamford. Since opening its first store in 2016, Arrow has established itself as a market leader in the state of Connecticut.

The acquisition of Arrow dispensaries allows Curaleaf to become vertically integrated into the state. The dispensaries will sell products from Curaleaf’s 60,000 square foot cultivation facility in Simsbury. They may also sell a selection of cannabis products from other producers in Connecticut.

Curaleaf CEO, Joe Lusardi, stated that the acquisition would reaffirm the company’s position as a leading cannabis operator in the US. He also commented on how the newly acquired dispensaries would operate during the COVID-19 crisis. 

“As with most Curaleaf dispensaries, Arrow will operate as an essential service business. This will allow Curaleaf to continue providing patients with the products they rely on during these challenging times. 

“Like all our dispensaries, Arrow has implemented the additional COVID-19 measures, to protect employees and patients while remaining open. We look forward to providing our products directly to Connecticut patients, and building a long-lasting relationship with them,” Joe said.

As an essential service, Curaleaf has implemented heightened safety and hygiene measures for while they are open. These include increased cleaning protocols, social distancing, new delivery options, curbside pickup, and dedicated hours for seniors and other high-risk groups. 

Curaleaf’s share price is up 5.25 per cent, and trading for $5.41 per share, as of 10:00am EST.

More From The Market Online
Cannabis Report image of farmed cannabis plants

The Market Online’s Weekly Cannabis Report – July 26, 2024

Tilray Oral Solution THC10:CBD10 cannabis extract, aka Tilray Solução Oral THC10:CBD10, has been approved for medical use in Portugal.
medical branch logo

Tilray approved for third medical cannabis product in Portugal

Tilray Medical, a subsidiary of Tilray Brands (TSX:TLRY) has been approved for a new medical cannabis extract in Portugal.